Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synercid PK in Pediatric Patients
NCT00240747Phase 3
Key facts
- Status
- Terminated
- Start
- Jun 2000
- Countries
- 1
- Sponsor
- Pfizer
- Modality
- Peptides, Small Molecules
- Drugs
- quinupristin
- Conditions
- Gram-positive bacterial infection
01
Overview
Phase 3, open-label, single-arm trial of quinupristin in Gram-positive bacterial infection, sponsored by Pfizer. Primary endpoint: Population pharmacokinetics. Started Jun 2000; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Synercid
Pediatric patients receiving I.V. Synercid
03
Who it enrols
Pediatric patients with serious, suspected or documented gram-positive infection.
04
Endpoints
Primary
Population pharmacokinetics
Secondary
Safety
Efficacy
Beyond the preview
Go deeper on NCT00240747.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240747.